EGFR and non-small cell lung carcinoma: Japanese nationwide surveillance of NSCLC with comorbid IP by Minegishi et al. revealed that the incidence rates of acute exacerbation after EGFR-TKI were 83.3% for first-line pharmacotherapy and 44.4% for second-line pharmacotherapy [17].